Park Avenue Securities LLC Purchases 156,175 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)

Park Avenue Securities LLC raised its position in shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPTGet Rating) by 289.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 210,176 shares of the company’s stock after acquiring an additional 156,175 shares during the period. Park Avenue Securities LLC’s holdings in Checkpoint Therapeutics were worth $372,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of CKPT. Qube Research & Technologies Ltd bought a new stake in Checkpoint Therapeutics during the fourth quarter valued at about $135,000. Advisor Group Holdings Inc. boosted its holdings in Checkpoint Therapeutics by 51.4% during the fourth quarter. Advisor Group Holdings Inc. now owns 98,503 shares of the company’s stock valued at $306,000 after acquiring an additional 33,440 shares during the period. Envestnet Asset Management Inc. boosted its holdings in Checkpoint Therapeutics by 12.0% during the fourth quarter. Envestnet Asset Management Inc. now owns 66,847 shares of the company’s stock valued at $208,000 after acquiring an additional 7,179 shares during the period. Alps Advisors Inc. bought a new stake in Checkpoint Therapeutics during the fourth quarter valued at about $301,000. Finally, Ironwood Investment Management LLC boosted its holdings in Checkpoint Therapeutics by 3.2% during the fourth quarter. Ironwood Investment Management LLC now owns 136,155 shares of the company’s stock valued at $423,000 after acquiring an additional 4,283 shares during the period. 11.87% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO James F. Oliviero III sold 228,000 shares of the stock in a transaction dated Friday, June 17th. The shares were sold at an average price of $1.09, for a total value of $248,520.00. Following the completion of the transaction, the chief executive officer now owns 2,610,003 shares of the company’s stock, valued at $2,844,903.27. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 264,000 shares of company stock valued at $288,060 over the last quarter. Corporate insiders own 6.10% of the company’s stock.

Checkpoint Therapeutics Stock Performance

NASDAQ CKPT opened at $1.05 on Wednesday. The firm has a 50-day simple moving average of $1.19 and a 200 day simple moving average of $1.61. Checkpoint Therapeutics, Inc. has a twelve month low of $0.96 and a twelve month high of $4.64. The stock has a market cap of $95.58 million, a PE ratio of -1.26 and a beta of 1.77.

Checkpoint Therapeutics (NASDAQ:CKPTGet Rating) last released its earnings results on Thursday, May 12th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.09). Checkpoint Therapeutics had a negative net margin of 26,592.46% and a negative return on equity of 173.15%. The company had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.07 million. Research analysts forecast that Checkpoint Therapeutics, Inc. will post -0.7 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, B. Riley reiterated a “buy” rating and issued a $7.00 target price on shares of Checkpoint Therapeutics in a research note on Thursday, July 14th.

Checkpoint Therapeutics Company Profile

(Get Rating)

Checkpoint Therapeutics, Inc, clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells.

See Also

Want to see what other hedge funds are holding CKPT? Visit to get the latest 13F filings and insider trades for Checkpoint Therapeutics, Inc. (NASDAQ:CKPTGet Rating).

Institutional Ownership by Quarter for Checkpoint Therapeutics (NASDAQ:CKPT)

Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with's FREE daily email newsletter.